Drug intelligence / Profile preview

GW-856464

Development stage: Discontinued
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

GW-856464 is a small molecule drug developed by GSK as a potent and selective antagonist of the melanin-concentrating hormone receptor 1 (MCHR1). It was investigated for the treatment of obesity and other metabolic diseases. The compound acts by inhibiting MCHR1, which is implicated in energy homeostasis and body weight regulation. Despite promising preclinical activity as an anti-obesity agent, clinical development was discontinued after phase 1 trials due to low bioavailability[2][6][7].

Other names: (R)-6-(4-chlorophenyl)-3-(4-(3-hydroxypyrrolidin-1-yl)-3-methoxyphenyl)thieno(3,2-d)pyrimidin-4(3H)-one6-(4-chlorophenyl)-3-(4-((3R)-3-hydroxypyrrolidin-1-yl)-3-methoxyphenyl)thieno(3,2-d)pyrimidin-4-one

Targets

MCHR1 (Melanin-concentrating hormone receptor 1)

Beyond the preview

Go deeper on GW-856464.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GW-856464.

Explore the full profile